Context Therapeutics Inc. increased its authorized shares of common stock from 100 million to 200 million, approved by stockholders at a Special Meeting on September 17, 2024, with 57.67% of shares represented. The final vote was 42,389,461 in favor, 790,853 against, and 71,655 abstentions.